The addition of tamoxifen to adjuvant chemotherapy for hormone receptor negative breast cancer does not appear to affect outcomes for postmenopausal patients.

Zdroj: Inpharma Weekly. 1/7/2006, Issue 1519, p17-37. 1/4p.
Databáze: Academic Search Ultimate
Externí odkaz: